R. Huber

发表

Soraprazan: Setting New Standards in Inhibition of Gastric Acid Secretion

W. Simon, J. Shin, M. Herrmann, 2007, Journal of Pharmacology and Experimental Therapeutics.

Differences in pH-Dependent Activation Rates of Substituted Benzimidazoles and Biological in vitro Correlates

V. Steinijans, M. Hartmann, R. Huber, 1998, Pharmacology.

Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.

W. Wurst, V. Steinijans, M. Hartmann, 1991, International journal of clinical pharmacology, therapy, and toxicology.

Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.

W. Wurst, V. Steinijans, H. Koch, 1995, International journal of clinical pharmacology and therapeutics.

Lack of pantoprazole drug interactions in man.

W. Wurst, V. Steinijans, M. Hartmann, 1994, International journal of clinical pharmacology and therapeutics.

The continuing development of proton pump inhibitors with particular reference to pantoprazole

G. Sachs, G. Sachs, W. Simon, 1995, Alimentary pharmacology & therapeutics.

No influence of pantoprazole on the pharmacokinetics of phenytoin.

R. Schall, V. Steinijans, H. Bliesath, 1995, International journal of clinical pharmacology and therapeutics.

Lack of Pharmacokinetic and Pharmacodynamic Interaction Between Pantoprazole and Glibenclamide in Humans

I. Walter‐Sack, W. Wurst, V. Steinijans, 1998 .

Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man

W. Wurst, V. Steinijans, M. Hartmann, 1996, European Journal of Clinical Pharmacology.

Lack of pharmacokinetic interaction of pantoprazole with diazepam in man.

U. Klotz, R. Gugler, W. Wurst, 1996, British journal of clinical pharmacology.

Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.

I. Meineke, W. Wurst, V. Steinijans, 1994, International journal of clinical pharmacology and therapeutics.

Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.

W. Wurst, R. Lühmann, M. Hartmann, 1990, Zeitschrift fur Gastroenterologie.

Single intravenous administration of the H+, K+‐ATPase inhibitor BY 1023/SK&F 96022—inhibition of pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man

W. Wurst, R. Lühmann, M. Hartmann, 1990, Alimentary pharmacology & therapeutics.

Lack of Influence of Pantoprazole on Cardiovascular Function in Healthy Volunteers

W. Wurst, M. Hartmann, R. Luehmann, 1995 .

Chapter 2 Determination of Drugs and Their Metabolites in Biological Samples by Fully Automated Hplc with on-line Solid-Liquid Extraction and Pre-Column Switching

R. Huber, K. Zech, 1988 .

Pharmacokinetics of pantoprazole in man.

V. Steinijans, R. Lühmann, M. Hartmann, 1996, International journal of clinical pharmacology and therapeutics.

Twenty‐four‐hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.

W. Wurst, M. Hartmann, H. Bliesath, 1996, Alimentary pharmacology & therapeutics.

Fluorescence labelling in trace analysis of biological samples: simultaneous determination of free fatty acids and related carboxylic compounds.

W. Voelter, R. Huber, K. Zech, 1981, Journal of chromatography.

High-performance liquid chromatographic determination of the H+/K+ ATPase inhibitor (BY 1023/SK&F 96,022) and its sulphone metabolite in serum or plasma by direct injection and fully automated pre-column sample clean-up.

W. Müller, S. J. Rogers, E. Doyle, 1990, Journal of chromatography.

Glucuronide conjugates of Soraprazan (BY359), a new potassium-competitive acid blocker (P-CAB) for the treatment of acid-related diseases

K. Lumbard, M. A. Holmes, P. Zimmermann, 2006 .

A simple high-performance liquid chromatographic pre-column technique for investigation of drug metabolism in biological fluids.

T. Kronbach, W. Voelter, R. Huber, 1982, Journal of chromatography.

The Effect of Previous Diet on Plaque pH Response to Different Foods

M. Sela, H. Sgan-Cohen, E. Newbrun, 1988, Journal of dental research.

Direct injection of biological fluids: Application of HPLC-analysis with precolumn enrichment to the pharmacokinetic studies of lonazolac

T. Kronbach, W. Voelter, R. Huber, 1982 .

Eltenac, a new anti-inflammatory and analgesic drug for horses: clinical aspects.

R. Lühmann, R. Huber, W. Prügner, 1991, Journal of veterinary pharmacology and therapeutics.

Determination of urapidil and its metabolites in human serum and urine: comparison of liquid-liquid and fully automated liquid-solid extraction.

R. Huber, K. Zech, 1986, Journal of chromatography.

Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet.

H. Mascher, P. Sander, P. Lücker, 2001, Methods and findings in experimental and clinical pharmacology.

Lack of pantoprazole drug interactions in man: an updated review.

W. Wurst, V. Steinijans, M. Hartmann, 1996, International journal of clinical pharmacology and therapeutics.

Lack of pharmacokinetic interaction as an equivalence problem.

V. Steinijans, M. Hartmann, H. Radtke, 1996, International journal of clinical pharmacology, therapy, and toxicology.

Effect of food on antacid neutralizing capacity in man

F. Halter, C. Bachmann, R. Huber, 1982, European journal of clinical investigation.

Pharmacokinetics and drug interactions--relevant factors for the choice of a drug.

V. Steinijans, H. Radtke, R. Huber, 1996, International journal of clinical pharmacology and therapeutics.

Lack of pharmacokinetic interaction between pantoprazole and diclofenac.

W. Wurst, V. Steinijans, H. Mascher, 1996, International journal of clinical pharmacology and therapeutics.

Pantoprazole does not interact with nifedipine in man under steady-state conditions.

W. Wurst, V. Steinijans, H. Koch, 1996, International journal of clinical pharmacology and therapeutics.

Intra‐oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro‐oesophageal reflux disease

H. Mascher, P. Sander, G. Gatz, 2003, European Journal of Gastroenterology and Hepathology.

Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration.

H. Mascher, P. Sander, P. Lücker, 1999, Methods and findings in experimental and clinical pharmacology.

Esomeprazole MUPS 40 mg tablets and esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine are bioequivalent.

B. Pfaffenberger, R. Huber, D. Knoerzer, 2005, International journal of clinical pharmacology and therapeutics.

Effect of repeated oral administration of BY 1023/SK&F 96022 – a new substituted benzimidazole derivative – on pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man

W. Wurst, R. Lühmann, P. Müller, 1990, Alimentary pharmacology & therapeutics.

Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration.

W. Wurst, R. Lühmann, M. Hartmann, 1996, International journal of clinical pharmacology and therapeutics.

Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.

W. Wurst, V. Steinijans, M. Hartmann, 1996, International journal of clinical pharmacology and therapeutics.

Pantoprazole does not interact with the pharmacokinetics of carbamazepine.

W. Wurst, V. Steinijans, H. Mascher, 1998, International journal of clinical pharmacology and therapeutics.